Table 2.
Included studies and relevant results
| Author | Design | LoE | Patients n | Mean age | Signs and symptoms | Diagnosis | Treatment | Outcome |
|---|---|---|---|---|---|---|---|---|
| Xiaoxu Lu, 2022 [13] | RS | IV | 11 | 30 | Hip and leg pain, ESR augmented in all patients, CRP in 5/11 | MRI | NSAIDs, betamethasone + ropivacaine + methylcobalamin SIJ injection (US or fluoroscopy guided), myofascial trigger points release | After 2–4 injections: VAS significantly lowered, provocative tests -, ESR and CRP normal |
| Ferias de-Aragão, 2021 [14] | CR | VI | 1 | 42 | LBP | US | Ropivacaine + methylprednisolone SIJ injection (US guided) | Complete improvement of pain |
| Savas Comlek, 2020 [12] | RS | IV | 20 | 31.0 ± 2.9 | LBP | MRI | Methylprednisolone + lidocaine SIJ injection (US guided) | Significant ODI and VAS reduction |
| Vincent, 2019 [15] | CR | VI | 1 | 30 | LBP | US | Lidocaine + triamcinolone acetonide SIJ injection | After procedure, VAS 0/10; after 14 days, VAS 2/10 |
| Paulsen Te, 1993 [16] | CR | VI | 1 | 32 | SIJ pain | n.r | Manual mobilization | The patient reported to be “very happy” after five treatments |
LoE level of evidence, N number, RS retrospective study, CR case report, MRI magnetic resonance imaging, US ultrasound, CT computed tomography, N.r not reported, SIJ sacroiliac joint, LBP low back pain, ESR erythrocyte sedimentation rate, CRP c-reactive protein, VAS visual analog scale and ODI Oswestry disability index